Myelodysplastic Syndromes

Our specialists provide expert care for people with myelodysplastic syndromes (MDS). These are conditions in which the blood-forming cells in the bone marrow are damaged, leading to a decreased number of red blood cells, white blood cells, or platelets. We use sophisticated testing to identify the type of MDS and determine the risk of the condition progressing. Then, we create a personalized and evidence-based treatment plan to meet your needs, ranging from watchful monitoring to stem cell transplantation.

Clinical Trials and Research Studies

Phase 3

A Phase 3 Randomized Multicenter Double-Blind Placebo-Controlled Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Learn More

Phase 1

A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia

Learn More

Phase 1

A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Learn More

Phase 6

A Multi-center Open-label Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL

Learn More